Overview

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy

Status:
Not yet recruiting

Trial end date:
2030-03-29

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Daiichi Sankyo, Inc.
SWOG Clinical Trials Partnership

Treatments:

Capecitabine
Durvalumab
Pembrolizumab